Since 2006, the European Commission has granted Conditional Marketing Authorizations (CMAs) for medicines where the benefit of immediate availability outweighs the risk of less comprehensive data than normally required in cases of severe/life-threatening disease, emergency situations or orphan medicines. However, to reach patients, medicines must also be publically reimbursed. This research aims to assess the reimbursement outcomes of major public payer bodies of all medicines approved under CMAs.
Authors: Macaulay R, Sutcliffe D, PAREXEL International, London, United Kingdom
To find out more about this poster you can register to download it here after the ISPOR event.